MEMPHIS, Tenn. -- FDX Corp., parent of No. 1 overnight-delivery company Federal Express, posted third-quarter profit that exceeded Wall Street expectations and set a 2-for-1 stock split. The company reported net income climbed to $78 …
FedEx Corporation (FDX - Free Report) is set to report third-quarter fiscal 2017 results after the closing bell on Mar 21. Last quarter, FedEx – a leading player in the field of global express delivery services – posted a negative surprise of …
[Business Wire] – A couple of special northern fur seals will have an unforgettable Valentine’s Day this year with a little …
FedEx
FedEx Corporation (Public, NYSE:FDX) reported better than expected earnings today of $0.76 per share versus the consensus estimate of $0.72. The “beat” was cited as a result of higher shipment growth that favorably impacted the …
FDX's buyback program is the company's first ever. The stock has fallen drastically since FDX announced lower-than-expected fiscal first-quarter earnings on Sept. 16. Meeting in Paris, just before the company's annual shareholder …
FedEx Corporation (FDX) is a freight and logistics company with operations across a number of transportation and commerce businesses and is set to report its most recent quarterly earnings on Tuesday after the bell. The company’s …
FedEx
Jim Mitarotonda urged the beauty products company to start a search for replace its CEO, Sheri McCoy, after a poor quarter. The technology could help the e-commerce giant streamline one of the most crucial steps in its delivery supply …
FedEx Corp. (NYSE: FDX) reported first-quarter fiscal 2015 results before ... FedEx repurchased 5.3 million shares of stock in the quarter, exhausting its share repurchase authorizations. The company said that share repurchases added …
Wall Street
With a market cap of 51445.82, FedEx Corporation (NYSE:FDX) has a large market cap size. FedEx Corporation (NYSE: FDX) has been on the stock market since its IPO date on the 4/12/1978. FedEx Corporation is in the Air Delivery & …
Auspex Pharmaceuticals (NASDAQ: ASPX) 83.6% HIGHER; announced positive topline efficacy and safety results from its Phase 3 registration trial evaluating SD-809 for the treatment of chorea associated with Huntington's disease (HD), …